Antibody therapy for rheumatoid arthritis - PubMed (original) (raw)
Review
Antibody therapy for rheumatoid arthritis
Peter C Taylor. Curr Opin Pharmacol. 2003 Jun.
Abstract
High-quality monoclonal antibodies (mAbs) with specificity for relevant disease molecules can now be produced in abundance. Anti-tumour necrosis factor-alpha therapies have set a new standard for symptom control in rheumatoid arthritis, and blockade of tumour necrosis factor has the potential to protect joints from structural damage. Other targets for therapeutic antibodies include the cytokines interleukin (IL)-1, IL-6, IL-8, IL-15, IL-17 and IL-18. In addition, there is preliminary evidence for the clinical efficacy of both keliximab, a mAb targeting the T cell antigen CD4, and rituximab, a chimeric mAb against the B cell antigen CD20 and CTLA4-Ig, which blocks the CD28/B7 interaction. Phase III studies have yet to be undertaken for these novel biological agents, and it is unclear whether any of these agents will have true disease-modifying capabilities.
Similar articles
- Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Feldmann M, Maini RN. Feldmann M, et al. Annu Rev Immunol. 2001;19:163-96. doi: 10.1146/annurev.immunol.19.1.163. Annu Rev Immunol. 2001. PMID: 11244034 Review. - Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F, Murdaca G, Ghio M, Indiveri F. Puppo F, et al. Autoimmun Rev. 2005 Nov;4(8):537-41. doi: 10.1016/j.autrev.2005.04.016. Autoimmun Rev. 2005. PMID: 16214092 Review. - Pro- and anti-inflammatory cytokines in rheumatoid arthritis.
Isomäki P, Punnonen J. Isomäki P, et al. Ann Med. 1997 Dec;29(6):499-507. doi: 10.3109/07853899709007474. Ann Med. 1997. PMID: 9562516 Review. - Treatment of rheumatoid arthritis with rituximab: an update and possible indications.
De Vita S, Quartuccio L. De Vita S, et al. Autoimmun Rev. 2006 Aug;5(7):443-8. doi: 10.1016/j.autrev.2006.02.007. Epub 2006 Mar 15. Autoimmun Rev. 2006. PMID: 16920570 Review. - Cytokines in rheumatoid arthritis: trials and tribulations.
Carteron NL. Carteron NL. Mol Med Today. 2000 Aug;6(8):315-23. doi: 10.1016/s1357-4310(00)01757-3. Mol Med Today. 2000. PMID: 10904249 Review.
Cited by
- Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors.
Murdaca G, Spanò F, Cagnati P, Puppo F. Murdaca G, et al. Redox Rep. 2013;18(3):95-9. doi: 10.1179/1351000213Y.0000000046. Epub 2013 May 10. Redox Rep. 2013. PMID: 23676793 Free PMC article. Review. - Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy.
Mercogliano MF, Bruni S, Mauro F, Elizalde PV, Schillaci R. Mercogliano MF, et al. Cancers (Basel). 2021 Feb 2;13(3):564. doi: 10.3390/cancers13030564. Cancers (Basel). 2021. PMID: 33540543 Free PMC article. Review. - The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.
Sørensen J, Andersen LS. Sørensen J, et al. Pharmacoeconomics. 2005;23(3):289-98. doi: 10.2165/00019053-200523030-00008. Pharmacoeconomics. 2005. PMID: 15836009 - Fed-batch culture optimization of a growth-associated hybridoma cell line in chemically defined protein-free media.
Gong X, Li D, Li X, Fang Q, Han X, Wu Y, Yang S, Shen BQ. Gong X, et al. Cytotechnology. 2006 Sep;52(1):25-38. doi: 10.1007/s10616-006-9026-3. Epub 2006 Dec 2. Cytotechnology. 2006. PMID: 19002863 Free PMC article. - The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation.
Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, Altuntas CZ, Sass Bak-Jensen K, McGeachy MJ, Do JS, Xiao H, Delgoffe GM, Min B, Powell JD, Tuohy VK, Cua DJ, Li X. Gulen MF, et al. Immunity. 2010 Jan 29;32(1):54-66. doi: 10.1016/j.immuni.2009.12.003. Epub 2010 Jan 7. Immunity. 2010. PMID: 20060329 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous